Skip to main content
no upcoming events

Please check back with us.

PIPELINE > TRIAL OVERVIEW

Molecule Overview
BAFF-R T-Cell Engager
LY4152199
BAFF-R MOA

van Loo PF, et al1; Dong Z, et al2

Target

B-cell activating factor receptor (BAFF-R) is a tumor necrosis factor (TNF) receptor superfamily member that is essential to B-cell development and survival.3 BAFF-R is expressed as a surface protein by most B cells and appears unaffected after CD19/20 loss.2,4 

Molecule

LY4152199 is a human BAFF-R x CD3 bispecific antibody that engages BAFF-R on the surface of B cells and CD3 on the surface of T cells, leading to T-cell-mediated elimination of BAFF-R expressing malignant B cells.5

Clinical Development

LY4152199 preclinical data support further evaluation in clinical trials.5

References

  1. van Loo PF, et al. T cell engaging bispecific antibodies generated from a novel, large and diverse CD3 panel demonstrate functionality uncoupled from affinity. Poster presented at: European Hematology Association Congress; May 14, 2020; Virtual. Poster EP1482.
  2. Dong Z, et al. Blood Adv. 2023;7(6):918-932.
  3. Rodig SJ, et al. Hum Pathol. 2005;36(10):1113-1119.
  4. Qin H, et al. Sci Transl Med. 2019;11(511):eaaw9414.
  5. Yang W, et al. Abstract presented at: American Society of Hematology; December 7-10, 2024; San Diego, CA. Abstract 2785.
For information on trial enrollment, locations, and more, call 1-800-545-5979.
REQUEST A MEDICAL SCIENCE LIAISON

or visit www.clinicaltrials.gov for more information on this trial